Peter Maag - Feb 7, 2024 Form 3 Insider Report for Kyverna Therapeutics, Inc. (KYTX)

Role
Chief Executive Officer, Director
Signature
By: /s/ Ryan Jones, as Attorney-in-Fact
Stock symbol
KYTX
Transactions as of
Feb 7, 2024
Transactions value $
$0
Form type
3
Date filed
2/7/2024, 09:55 PM
Previous filing
Jan 5, 2024
Next filing
Apr 8, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding KYTX Common Stock 58.2K Feb 7, 2024 Direct
holding KYTX Common Stock 349K Feb 7, 2024 By The Maag Family Irrevocable Trust

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding KYTX Stock Option (Right to Buy) Feb 7, 2024 Common Stock 330K $4.83 Direct F1
holding KYTX Stock Option (Right to Buy) Feb 7, 2024 Common Stock 1.1K $4.33 Direct F2
holding KYTX Stock Option (Right to Buy) Feb 7, 2024 Common Stock 990K $3.15 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the original number of shares subject to the option shall vest on January 1, 2025, and 1/48th of the original number of shares subject to the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service.
F2 25% of the original number of shares subject to the option shall vest on July 1, 2024, and 1/48th of the original number of shares subject to the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service.
F3 25% of the original number of shares subject to the option vested on October 13, 2023, and 1/48th of the original number of shares subject to the option vested or shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service.

Remarks:

Exhibit 24 - Power of Attorney